{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:38:40Z","timestamp":1793306320146,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s11239-015-1310-7","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T18:38:47Z","timestamp":1452969527000},"page":"206-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":292,"title":["Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment"],"prefix":"10.1007","volume":"41","author":[{"given":"Allison E.","family":"Burnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Mahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara R.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn B.","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,16]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T Hulle Van der","year":"2014","unstructured":"Van der Hulle T, Kooiman J, den Exter PL et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320\u2013328. doi: 10.1111\/jth.12485","journal-title":"J Thromb Haemost"},{"key":"1310_CR2","author":"S Mantha","year":"2014","unstructured":"Mantha S, Ansell J (2014) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. doi: 10.1007\/s11239-014-1102-5","journal-title":"J Thromb Thrombolysis"},{"key":"1310_CR3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709\u2013718. doi: 10.1056\/NEJMoa1113697","journal-title":"N Engl J Med"},{"key":"1310_CR4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510. doi: 10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"key":"1310_CR5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699\u2013708. doi: 10.1056\/NEJMoa1207541","journal-title":"N Engl J Med"},{"key":"1310_CR6","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352. doi: 10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"key":"1310_CR7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764\u2013772. doi: 10.1161\/CIRCULATIONAHA.113.004450","journal-title":"Circulation"},{"key":"1310_CR8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"EINSTEIN\u2013PE Investigators, B\u00fcller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287\u20131297. doi: 10.1056\/NEJMoa1113572","journal-title":"N Engl J Med"},{"key":"1310_CR9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808. doi: 10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"key":"1310_CR10","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"FN Buller","year":"2013","unstructured":"Buller FN, Hokusai-VTE Investigators et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415. doi: 10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"key":"1310_CR11","unstructured":"XARELTO-PM-ENG-10JUL2014-172618.pdf. http:\/\/www.bayer.ca\/files\/XARELTO-PM-ENG-10JUL2014-172618.pdf ? Accessed 11 Nov 2014"},{"key":"1310_CR12","unstructured":"Boehringer Ingelheim Canada Ltd (2014) Pradaxa product monograph. http:\/\/www.boehringeringelheim.ca\/content\/dam\/internet\/opu\/ca_EN\/documents\/humanhealth\/product_monograph\/PradaxaPMEN.pdf . Accessed 11 Nov 2014"},{"key":"1310_CR13","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/AOG.0000000000000277","volume":"123","author":"P Bapat","year":"2014","unstructured":"Bapat P, Kedar R, Lubetsky A et al (2014) Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 123:1256\u20131261. doi: 10.1097\/AOG.0000000000000277","journal-title":"Obstet Gynecol"},{"key":"1310_CR14","author":"O K\u00f6nigsbr\u00fcgge","year":"2014","unstructured":"K\u00f6nigsbr\u00fcgge O, Langer M, Hayde M et al (2014) Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost. doi: 10.1160\/TH14-04-0393","journal-title":"Thromb Haemost"},{"key":"1310_CR15","unstructured":"Pfizer Canada Inc Eliquis Product Monograph. http:\/\/www.pfizer.ca\/en\/our_products\/products\/monograph\/313 . Accessed 11 Nov 2014"},{"key":"1310_CR16","unstructured":"Savaysa Edoxaban PI. http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true . Accessed 22 Sept 2015"},{"key":"1310_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","volume":"47","author":"DJ Stangier","year":"2008","unstructured":"Stangier DJ, St\u00e4hle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47\u201359. doi: 10.2165\/00003088-200847010-00005","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 2","key":"1310_CR18","first-page":"455","volume":"7","author":"CE Frost","year":"2009","unstructured":"Frost CE, Nepal S, Barrett Y et al (2009) Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost 7(suppl 2):455","journal-title":"J Thromb Haemost"},{"key":"1310_CR19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC et al (2013) Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 76:908\u2013916","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1310_CR20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmakokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47(2):218\u2013226","journal-title":"J Clin Pharmacol"},{"key":"1310_CR21","unstructured":"Schulman S et al (2014) ASH 56th annual meeting San Francisco, CA Dec 2014, session 332 abstract 1544"},{"key":"1310_CR22","author":"K Win","year":"2014","unstructured":"Win K, Rodgers GM (2014) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. doi: 10.1002\/ajh.23797","journal-title":"Am J Hematol"},{"key":"1310_CR23","author":"JK Schaefer","year":"2014","unstructured":"Schaefer JK, McBane RD, Black DF et al (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. doi: 10.1160\/TH14-03-0272","journal-title":"Thromb Haemost"},{"key":"1310_CR24","doi-asserted-by":"crossref","first-page":"e114445","DOI":"10.1371\/journal.pone.0114445","volume":"9","author":"TB Larsen","year":"2014","unstructured":"Larsen TB, Nielsen PB, Skjoth F et al (2014) Non-vitamin antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi-systematic review and meta-analysis of safety and efficacy outcomes. PLoS ONE 9:e114445","journal-title":"PLoS ONE"},{"key":"1310_CR25","author":"MC Vedovati","year":"2014","unstructured":"Vedovati MC, Germini F, Agnelli G, Becattini C (2014) Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest. doi: 10.1378\/chest.14-0402","journal-title":"Chest"},{"key":"1310_CR26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","volume":"12","author":"T Hulle van der","year":"2014","unstructured":"van der Hulle T, den Exter PL, Kooiman J et al (2014) Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 12:1116\u20131120","journal-title":"J Thromb Haemost"},{"key":"1310_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MJT.0000000000000055","volume":"22","author":"P Sardar","year":"2015","unstructured":"Sardar P, Chatterjee S, Herzog E et al (2015) New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther 22:460\u2013468","journal-title":"Am J Ther"},{"key":"1310_CR28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AYY Lee","year":"2003","unstructured":"Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153. doi: 10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"issue":"15","key":"1310_CR29","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729\u20131735","journal-title":"Arch Intern Med"},{"issue":"12","key":"1310_CR30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062\u20131072","journal-title":"Am J Med"},{"key":"1310_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","volume":"12","author":"SR Deitcher","year":"2006","unstructured":"Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u00a0day period. Clin Appl Thromb Hemost 12:389\u2013396","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"1310_CR32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"A Lee","year":"2015","unstructured":"Lee A, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677\u2013686. doi: 10.0001\/jama.2015.9243","journal-title":"JAMA"},{"issue":"2","key":"1310_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M et al (2015) Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131(2):157\u2013164","journal-title":"Circulation"},{"key":"1310_CR34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamainternmed.2013.12217","volume":"174","author":"I Sipahi","year":"2014","unstructured":"Sipahi I, Celik S, Tozun N (2014) A comparison of results of the us food and drug administration\u2019s mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med 174:150\u2013151. doi: 10.1001\/jamainternmed.2013.12217","journal-title":"JAMA Intern Med"},{"issue":"15","key":"1310_CR35","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","volume":"124","author":"C Chai-Adisaksopha","year":"2014","unstructured":"Chai-Adisaksopha C, Crowther M, Isayama T, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systemic review and meta-analysis. Blood 124(15):2450\u20132458","journal-title":"Blood"},{"issue":"2 Suppl","key":"1310_CR36","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease. Chest 141(2 Suppl):e419S\u2013e494S. doi: 10.1378\/chest.11-2301","journal-title":"Chest"},{"key":"1310_CR37","first-page":"CD001100","volume":"9","author":"PM Erkens","year":"2010","unstructured":"Erkens PM, Prins MH (2010) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 9:CD001100","journal-title":"Cochrane Database Syst Rev"},{"key":"1310_CR38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/asheducation.V2012.1.460.3798662","volume":"2012","author":"DM Funk","year":"2012","unstructured":"Funk DM (2012) Coagulation assays and anticoagulant monitoring. Hematology 2012:460\u2013465. doi: 10.1182\/asheducation-2012.1.460","journal-title":"Hematology"},{"key":"1310_CR39","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2012-12-453076","volume":"121","author":"A Tripodi","year":"2013","unstructured":"Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032\u20134035. doi: 10.1182\/blood-2012-12-453076","journal-title":"Blood"},{"key":"1310_CR40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","volume":"64","author":"A Cuker","year":"2014","unstructured":"Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64:1128\u20131139. doi: 10.1016\/j.jacc.2014.05.065","journal-title":"J Am Coll Cardiol"},{"key":"1310_CR41","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","volume":"141","author":"J Douketis","year":"2012","unstructured":"Douketis J (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: ACCP. Chest 141:e326S\u2013e350S","journal-title":"Chest"},{"key":"1310_CR42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","volume":"126","author":"JS Healey","year":"2012","unstructured":"Healey JS, Eikelboom J, Douketis J et al (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126:343\u2013348. doi: 10.1161\/CIRCULATIONAHA.111.090464","journal-title":"Circulation"},{"key":"1310_CR43","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"MW Sherwood","year":"2014","unstructured":"Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129:1850\u20131859. doi: 10.1161\/CIRCULATIONAHA.113.005754","journal-title":"Circulation"},{"issue":"25","key":"1310_CR44","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2014-08-595496","volume":"124","author":"D Garcia","year":"2014","unstructured":"Garcia D, Alexander JH, Wallentin L et al (2014) Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures. Blood 124(25):3692\u20133698","journal-title":"Blood"},{"key":"1310_CR45","doi-asserted-by":"crossref","unstructured":"Horlocker TT, Wedel DJ, Rowlingson JC et al (2010) Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (3rd Edition). Reg Anesth Pain Med 35(1):64\u2013101 https:\/\/www.ismp.org\/newsletters\/acutecare\/issue.aspx?id=82 . Accessed 27 Nov 2014","DOI":"10.1097\/AAP.0b013e3181c15c70"},{"key":"1310_CR46","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2012-06-415943","volume":"120","author":"AC Spyropoulos","year":"2012","unstructured":"Spyropoulos AC, Douketis JD (2012) How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120:2954\u20132962. doi: 10.1182\/blood-2012-06-415943","journal-title":"Blood"},{"key":"1310_CR47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMra1206531","volume":"368","author":"TH Baron","year":"2013","unstructured":"Baron TH, Kamath PS, McBane RD (2013) Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 368:2113\u20132124. doi: 10.1056\/NEJMra1206531","journal-title":"N Engl J Med"},{"key":"1310_CR48","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler JD, Grip LT, Mendell J, Giugliano RP (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61:2495\u20132502. doi: 10.1016\/j.jacc.2013.02.058","journal-title":"J Am Coll Cardiol"},{"key":"1310_CR49","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","volume":"29","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB (2013) Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 29:S24\u201333. doi: 10.1016\/j.cjca.2013.04.002","journal-title":"Can J Cardiol"},{"issue":"6","key":"1310_CR50","first-page":"388","volume":"16","author":"J Feinberg","year":"2014","unstructured":"Feinberg J, Grabowitz L, Rotman-Pikielny P et al (2014) Dabigatran etexilate linked to fatal gastrointestinal hemorrhage. Isr Med Assoc 16(6):388\u2013389","journal-title":"Isr Med Assoc"},{"key":"1310_CR51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5811\/westjem.2014.2.19440","volume":"15","author":"JC-Y Lo","year":"2014","unstructured":"Lo JC-Y, Gerona RR (2014) A case of rivaroxaban associated intracranial hemorrhage. West J Emerg Med 15:375\u2013377. doi: 10.5811\/westjem.2014.2.19440","journal-title":"West J Emerg Med"},{"key":"1310_CR52","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.ijcard.2013.03.185","volume":"167","author":"C St\u00f6llberger","year":"2013","unstructured":"St\u00f6llberger C, Zuntner G, Bastovansky A, Finsterer J (2013) Cerebral hemorrhage under rivaroxaban. Int J Cardiol 167:e179\u2013e181. doi: 10.1016\/j.ijcard.2013.03.185","journal-title":"Int J Cardiol"},{"key":"1310_CR53","first-page":"110","volume":"126","author":"C Fountzilas","year":"2013","unstructured":"Fountzilas C, George J, Levine R (2013) Dabigatran overdose secondary to acute kidney injury and amiodarone use. N Z Med J 126:110\u2013112","journal-title":"N Z Med J"},{"key":"1310_CR54","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.hrtlng.2014.03.004","volume":"43","author":"C St\u00f6llberger","year":"2014","unstructured":"St\u00f6llberger C, Finsterer J (2014) Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state. Heart Lung 43:262\u2013263. doi: 10.1016\/j.hrtlng.2014.03.004","journal-title":"Heart Lung"},{"key":"1310_CR55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","volume":"10","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264\u2013271. doi: 10.1016\/j.amjopharm.2012.05.002","journal-title":"Am J Geriatr Pharmacother"},{"key":"1310_CR56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","volume":"366","author":"P Harper","year":"2012","unstructured":"Harper P, Young L, Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864\u2013866. doi: 10.1056\/NEJMc1112874","journal-title":"N Engl J Med"},{"key":"1310_CR57","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C et al (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: ACCP evidence-based clinical practice guidelines (8th edn). Chest 133:257S\u2013298S","journal-title":"Chest"},{"key":"1310_CR58","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2011","unstructured":"Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate a new oral thrombin inhibitor. Circulation 123:1436\u20131450. doi: 10.1161\/CIRCULATIONAHA.110.004424","journal-title":"Circulation"},{"key":"1310_CR59","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","volume":"9","author":"K-H Liesenfeld","year":"2011","unstructured":"Liesenfeld K-H, Lehr T, Dansirikul C et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9:2168\u20132175. doi: 10.1111\/j.1538-7836.2011.04498.x","journal-title":"J Thromb Haemost"},{"key":"1310_CR60","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB et al (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32:2781\u20132789. doi: 10.1093\/eurheartj\/ehr113","journal-title":"Eur Heart J"},{"key":"1310_CR61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319. doi: 10.1056\/NEJMoa1112277","journal-title":"N Engl J Med"},{"key":"1310_CR62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699\u2013708. doi: 10.1056\/NEJMoa1105819","journal-title":"N Engl J Med"},{"key":"1310_CR63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","volume":"174","author":"BL Davidson","year":"2014","unstructured":"Davidson BL, Verheijen S, Lensing AA et al (2014) Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174:947\u2013953. doi: 10.1001\/jamainternmed.2014.946","journal-title":"JAMA Intern Med"},{"key":"1310_CR64","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891. doi: 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"1310_CR65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. doi: 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"1310_CR66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11239-014-1060-y","volume":"37","author":"E Abo-Salem","year":"2014","unstructured":"Abo-Salem E, Becker R (2014) Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians. J Thromb Thrombolysis 37:372\u2013379. doi: 10.1007\/s11239-014-1060-y","journal-title":"J Thromb Thrombolysis"},{"key":"1310_CR67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjcard.2013.03.046","volume":"112","author":"JK Atay","year":"2013","unstructured":"Atay JK, Fanikos J, Barnes GD et al (2013) Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol 112:387\u2013389. doi: 10.1016\/j.amjcard.2013.03.046","journal-title":"Am J Cardiol"},{"key":"1310_CR68","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/jth.12662","volume":"12","author":"A Potteg\u00e5rd","year":"2014","unstructured":"Potteg\u00e5rd A, Poulsen BK, Larsen MD, Hallas J (2014) Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost 12:1413\u20131418","journal-title":"J Thromb Haemost"},{"key":"1310_CR69","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151. doi: 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"1310_CR70","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104. doi: 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"1310_CR71","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","volume":"128","author":"A Majeed","year":"2013","unstructured":"Majeed A, Hwang H-G, Connolly SJ et al (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128:2325\u20132332. doi: 10.1161\/CIRCULATIONAHA.113.002332","journal-title":"Circulation"},{"key":"1310_CR72","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","volume":"35","author":"JP Piccini","year":"2014","unstructured":"Piccini JP, Garg J, Patel MR et al (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873\u20131880. doi: 10.1093\/eurheartj\/ehu083","journal-title":"Eur Heart J"},{"key":"1310_CR73","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","volume":"63","author":"E Hylek","year":"2014","unstructured":"Hylek E, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial: predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63:2141\u20132147","journal-title":"J Am Coll Cardiol"},{"key":"1310_CR74","unstructured":"Research C for DE and drug safety and availability\u2014FDA Drug Safety Communication: FDA study of medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm396470.htm . Accessed 27 Nov 2014"},{"key":"1310_CR75","author":"DM Siegal","year":"2014","unstructured":"Siegal DM, Cuker A (2014) Reversal of target-specific oral anticoagulants. Drug Discov Today. doi: 10.1016\/j.drudis.2014.05.013","journal-title":"Drug Discov Today"},{"issue":"21","key":"1310_CR76","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood.V118.21.2316.2316","volume":"118","author":"J Ryn Van","year":"2011","unstructured":"Van Ryn J, Schurer J, Kink-Eiband M, Clemens A (2011) The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 118(21):1004","journal-title":"Blood"},{"issue":"s-1","key":"1310_CR77","first-page":"148","volume":"93","author":"J Ryn Van","year":"2008","unstructured":"Van Ryn J et al (2008) 13th congress of the European Hematology Association, Copenhagen, Denmark, June 12\u201315, 2008. Haematologica 93(s-1):148","journal-title":"Haematologica"},{"issue":"9","key":"1310_CR78","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","volume":"10","author":"I Pragst","year":"2012","unstructured":"Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G et al (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model. J Thromb Haemostas 10(9):1841\u20131848","journal-title":"J Thromb Haemostas"},{"issue":"4","key":"1310_CR79","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","volume":"168","author":"AC Martin","year":"2013","unstructured":"Martin AC, LeBonniec B, Fischer AM (2013) Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. J Int Card 168(4):4228\u20134233. doi: 10.1016\/j.ijcard.2013.07.152","journal-title":"J Int Card"},{"issue":"1","key":"1310_CR80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1160\/TH12-12-0907","volume":"110","author":"E Perzborn","year":"2013","unstructured":"Perzborn E, Gruber A, Tinel H et al (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 110(1):162\u2013172","journal-title":"Thromb Haemost"},{"key":"1310_CR81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","volume":"131","author":"H Zahir","year":"2015","unstructured":"Zahir H, Brown KS, Vandell AG et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82\u201390","journal-title":"Circulation"},{"issue":"1","key":"1310_CR82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","volume":"116","author":"A Godier","year":"2012","unstructured":"Godier A, Miclot A, LeBonniec B, Durand M, Fischer A-M, Emmerich J et al (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94\u2013102","journal-title":"Anesthesiology"},{"key":"1310_CR83","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","volume":"108","author":"R Marlu","year":"2012","unstructured":"Marlu R, Hodaj E, Paris A et al (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex vivo study in healthy volunteers. Thromb Haemost 108:217\u2013247","journal-title":"Thromb Haemost"},{"key":"1310_CR84","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"1214","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 1214:1573\u20131579","journal-title":"Circulation"},{"issue":"5","key":"1310_CR85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CCM.0b013e31827caaa3","volume":"41","author":"WE Dager","year":"2013","unstructured":"Dager WE, Gosselin RC, Roberts AJ et al (2013) Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 41(5):42\u201346","journal-title":"Crit Care Med"},{"key":"1310_CR86","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","volume":"106","author":"F Dentali","year":"2011","unstructured":"Dentali F, Marchesi C, Pierfranceschi MG et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost 106:429\u2013438. doi: 10.1160\/TH11-01-0052","journal-title":"Thromb Haemost"},{"key":"1310_CR87","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","volume":"363","author":"M Levi","year":"2010","unstructured":"Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363:1791\u20131800. doi: 10.1056\/NEJMoa1006221","journal-title":"N Engl J Med"},{"key":"1310_CR88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2013-09-529784","volume":"123","author":"DM Siegal","year":"2014","unstructured":"Siegal DM, Garcia DA, Crowther MA (2014) How I treat target-specific oral anticoagulant\u2013associated bleeding. Blood 123:1152\u20131158. doi: 10.1182\/blood-2013-09-529784","journal-title":"Blood"},{"key":"1310_CR89","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","volume":"87","author":"S Kaatz","year":"2012","unstructured":"Kaatz S, Kouides PA, Garcia DA et al (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87:S141\u2013S145. doi: 10.1002\/ajh.23202","journal-title":"Am J Hematol"},{"key":"1310_CR90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-013-0923-y","volume":"36","author":"S Kaatz","year":"2013","unstructured":"Kaatz S, Crowther M (2013) Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 36:195\u2013202. doi: 10.1007\/s11239-013-0923-y","journal-title":"J Thromb Thrombolysis"},{"key":"1310_CR91","unstructured":"van Ryn J et al (2014) American Heart Association Scientific Sessions 2014, Chicago, USA. http:\/\/www.abstractsonline.com\/pp8\/#!\/3547\/presentation\/41579"},{"key":"1310_CR92","unstructured":"Glund S (2013) 17765\u2014A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Paper presented at the American Heart Association Scientific Sessions, Dallas, Texas, 16\u201320 November 2013"},{"key":"1310_CR93","unstructured":"NCT02104947 clinicaltrials.gov"},{"key":"1310_CR94","volume-title":"European society of cardiology annual meeting","author":"A Hutchchaleelaha","year":"2012","unstructured":"Hutchchaleelaha A et al (2012) European society of cardiology annual meeting. Munich, Germany 27"},{"issue":"4","key":"1310_CR95","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","volume":"19","author":"G Lu","year":"2013","unstructured":"Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446\u2013451","journal-title":"Nat Med"},{"key":"1310_CR96","unstructured":"Crowther M; ASH 2014 San Francisco abstract #4269 Session 332. antithrombotic therapy: poster III Monday, December 8"},{"key":"1310_CR97","unstructured":"Crowther M, et al; ASH 2013. Abstract 3636, session 332. antithrombotic therapy: poster III Monday, December 9, 2013"},{"key":"1310_CR98","unstructured":"Crowther M, et al. ISTH 2013 Amsterdam"},{"key":"1310_CR99","unstructured":"A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02220725?term=NCT02220725&rank=1 . Accessed 27 Nov 2014"},{"key":"1310_CR100","unstructured":"A study in older subjects to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of apixaban\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207725?term=NCT02207725&rank=1 . Accessed 27 Nov 2014"},{"key":"1310_CR101","unstructured":"Laulicht B, Bakhru S, Jiang X, et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June 29\u2013July 4, 2013. Abstract ( http:\/\/www.eventure-online.com\/enenture\/publicAbstractView.do?id=2267118&congressId=6839"},{"key":"1310_CR102","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med 371:2141\u20132142","journal-title":"N Eng J Med"},{"issue":"6","key":"1310_CR103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373(6):511\u2013520. doi: 10.1056\/NEJMoa1502000","journal-title":"N Engl J Med"},{"key":"1310_CR104","unstructured":"Crowther MA, et al (2015) ISTH Congress 2015 abstract LB004"},{"key":"1310_CR105","unstructured":"Burton R (2012) Improving care transitions. Robert Wood Johnson Foundation Health Policy Brief Sept 13, 2012. www.rwjf.org\/content\/dam\/farm\/reports\/issue_briefs\/2012\/rwjf401314"},{"key":"1310_CR106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/jhm.910","volume":"6","author":"J Schillig","year":"2011","unstructured":"Schillig J, Kaatz S, Hudson M et al (2011) Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med 6:322\u2013328. doi: 10.1002\/jhm.910","journal-title":"J Hosp Med"},{"key":"1310_CR107","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1345\/aph.1R686","volume":"47","author":"CT Makowski","year":"2013","unstructured":"Makowski CT, Jennings DL, Nemerovski CW et al (2013) The impact of pharmacist-directed patient education and anticoagulant care coordination on patient satisfaction. Ann Pharmacother 47:805\u2013810. doi: 10.1345\/aph.1R686","journal-title":"Ann Pharmacother"},{"key":"1310_CR108","author":"AC Spyropoulos","year":"2014","unstructured":"Spyropoulos AC, Viscusi A, Singhal N et al (2014) Features of electronic health records necessary for the delivery of optimized anticoagulant therapy consensus of the EHR Task Force of the New York State Anticoagulation Coalition. Ann Pharmacother. doi: 10.1177\/1060028014555176","journal-title":"Ann Pharmacother"},{"key":"1310_CR109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/postgradmedj-2013-132474","volume":"90","author":"RPW Cowell","year":"2014","unstructured":"Cowell RPW (2014) Direct oral anticoagulants: integration into clinical practice. Postgrad Med J 90:529\u2013539. doi: 10.1136\/postgradmedj-2013-132474","journal-title":"Postgrad Med J"},{"key":"1310_CR110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JMDH.S44068","volume":"6","author":"F Michota","year":"2013","unstructured":"Michota F (2013) Transitions of care in anticoagulated patients. J Multidiscip Healthc 6:215\u2013228. doi: 10.2147\/JMDH.S44068","journal-title":"J Multidiscip Healthc"},{"key":"1310_CR111","doi-asserted-by":"crossref","first-page":"298","DOI":"10.18553\/jmcp.2000.6.4.298","volume":"6","author":"AC Spyropoulos","year":"2000","unstructured":"Spyropoulos AC, Kardos J, Wigal P (2000) Outcome analyses of the outpatient treatment of venous thromboemolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization. J Manag Care Pharm 6:298\u2013304","journal-title":"J Manag Care Pharm"},{"key":"1310_CR112","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","volume":"170","author":"D Jim\u00e9nez","year":"2010","unstructured":"Jim\u00e9nez D, Aujesky D, Moores L et al (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170:1383\u20131389. doi: 10.1001\/archinternmed.2010.199","journal-title":"Arch Intern Med"},{"key":"1310_CR113","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M et al (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625\u2013651. doi: 10.1093\/europace\/eut083","journal-title":"Europace"},{"key":"1310_CR114","unstructured":"James, J (2013) patient engagement. In: Health affairs. http:\/\/www.healthaffairs.org\/healthpolicybriefs\/brief.php?brief_id=86 . Accessed 27 Nov 2014"},{"key":"1310_CR115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1377\/hlthaff.2012.1064","volume":"32","author":"JH Hibbard","year":"2013","unstructured":"Hibbard JH, Greene J, Overton V (2013) Patients with lower activation associated with higher costs; delivery systems should know their patients\u2019 \u201cScores\u201d. Health Aff 32:216\u2013222. doi: 10.1377\/hlthaff.2012.1064","journal-title":"Health Aff"},{"key":"1310_CR116","author":"A Johnson","year":"2003","unstructured":"Johnson A, Sandford J, Tyndall J (2003) Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD003716","journal-title":"Cochrane Database Syst Rev"},{"key":"1310_CR117","unstructured":"Institute for Safe Medication Practices (ISMP) (2003) https:\/\/www.ismp.org\/Survey\/surveyresults\/NursingSurvey.asp . Accessed 27 Nov 2014"},{"issue":"1","key":"1310_CR118","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jth.12038","volume":"11","author":"W Ageno","year":"2013","unstructured":"Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G et al (2013) Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11(1):177\u2013179","journal-title":"J Thromb Haemost"},{"key":"1310_CR119","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","volume":"2013","author":"KA Bauer","year":"2013","unstructured":"Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464\u2013470. doi: 10.1182\/asheducation-2013.1.464","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"1310_CR120","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMe1307413","volume":"369","author":"M Cushman","year":"2013","unstructured":"Cushman M (2013) Treating acute venous thromboembolism\u2014shift with Care. N Engl J Med 369(9):865\u2013866","journal-title":"N Engl J Med"},{"key":"1310_CR121","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7861\/clinmedicine.14-2-165","volume":"14","author":"J Thachil","year":"2014","unstructured":"Thachil J (2014) The newer direct oral anticoagulants: a practical guide. Clin Med 14:165\u2013175. doi: 10.7861\/clinmedicine.14-2-165","journal-title":"Clin Med"},{"key":"1310_CR122","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/asheducation.V2012.1.536.3798545","volume":"2012","author":"JI Weitz","year":"2012","unstructured":"Weitz JI, Gross PL (2012) New oral anticoagulants: which one should my patient use? Hematology 2012:536\u2013540. doi: 10.1182\/asheducation-2012.1.536","journal-title":"Hematology"},{"issue":"4","key":"1310_CR123","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1160\/TH13-09-0803","volume":"111","author":"S Schulman","year":"2014","unstructured":"Schulman S (2014) New oral anticoagulant agents\u2014general features and outcomes in subsets of patients. Thromb Haemost 111(4):575\u2013582","journal-title":"Thromb Haemost"},{"key":"1310_CR124","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/1076029612470967","volume":"19","author":"CE Mahan","year":"2013","unstructured":"Mahan CE, Spyropoulos AC, Fisher MD et al (2013) Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. Clin Appl Thromb Hemost 19:504\u2013512. doi: 10.1177\/1076029612470967","journal-title":"Clin Appl Thromb Hemost"},{"key":"1310_CR125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1378\/chest.09-3081","volume":"139","author":"H Decousus","year":"2011","unstructured":"Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the improve investigators. Chest 139:69\u201379. doi: 10.1378\/chest.09-3081","journal-title":"Chest"},{"key":"1310_CR126","unstructured":"IPRO MAPP tool. http:\/\/qio.ipro.org\/wp-content\/uploads\/2012\/12\/MAP2014_5_01.pdf"},{"key":"1310_CR127","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1161\/STROKEAHA.114.005117","volume":"45","author":"S Kaatz","year":"2014","unstructured":"Kaatz S, Mahan CE (2014) Stroke prevention in patients with atrial fibrillation and renal dysfunction. Stroke 45:2497\u20132505. doi: 10.1161\/STROKEAHA.114.005117","journal-title":"Stroke"},{"key":"1310_CR128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0034-1381233","volume":"40","author":"G Lippi","year":"2014","unstructured":"Lippi G, Favaloro EJ, Mattiuzzi C (2014) Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring. Semin Thromb Hemost 40:756\u2013765","journal-title":"Semin Thromb Hemost"},{"key":"1310_CR129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","volume":"38","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang D, Raghavan N et al (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38:448\u2013458","journal-title":"Drug Metab Dispos"},{"key":"1310_CR130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","volume":"74","author":"S H\u00e4rtter","year":"2012","unstructured":"H\u00e4rtter S, Koenen-Bergmann M, Sharma A et al (2012) Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74:490\u2013500. doi: 10.1111\/j.1365-2125.2012.04218.x","journal-title":"Br J Clin Pharmacol"},{"key":"1310_CR131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/dmd.113.053769","volume":"42","author":"W Kishimoto","year":"2014","unstructured":"Kishimoto W, Ishiguro N, Ludwig-Schwellinger E et al (2014) In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2\/IC50 threshold. Drug Metab Dispos 42:257\u2013263. doi: 10.1124\/dmd.113.053769","journal-title":"Drug Metab Dispos"},{"key":"1310_CR132","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N et al (2013) Drug\u2013drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331\u2013342. doi: 10.1007\/s40256-013-0029-0","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"1310_CR133","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/bcp.12055","volume":"76","author":"X Delavenne","year":"2013","unstructured":"Delavenne X, Ollier E, Basset T et al (2013) A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 76(1):107\u2013113. doi: 10.1111\/bcp.12055","journal-title":"Br J Clin Pharmacol"},{"key":"1310_CR134","volume-title":"The top 100 drug interactions: a guide to patient management","author":"PD Hansten","year":"2012","unstructured":"Hansten PD, Horn JR (2012) The top 100 drug interactions: a guide to patient management, 2012th edn. Freeland, WA","edition":"2012"},{"key":"1310_CR135","unstructured":"FDA document: drug interactions and labeling\u00a0>\u00a0drug development and drug interactions: table of substrates, inhibitors, and inducers. http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm"},{"key":"1310_CR136","first-page":"A6568","volume":"157","author":"AJ Risselada","year":"2013","unstructured":"Risselada AJ, Visser MJ, van Roon EN (2013) Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd 157:A6568","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1310_CR137","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3324\/haematol.2013.097287","volume":"99","author":"R Altena","year":"2014","unstructured":"Altena R, van Roon E, Folkeringa R et al (2014) Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica 99:e26\u2013e27. doi: 10.3324\/haematol.2013.097287","journal-title":"Haematologica"},{"key":"1310_CR138","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455\u2013466. doi: 10.1111\/bcp.12075","journal-title":"Br J Clin Pharmacol"},{"key":"1310_CR139","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","volume":"338","author":"MJ Gnoth","year":"2011","unstructured":"Gnoth MJ, Buetehorn U, Muenster U et al (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372\u2013380. doi: 10.1124\/jpet.111.180240","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-015-1310-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1310-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T20:21:18Z","timestamp":1654114878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-015-1310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s11239-015-1310-7","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}